Real-time funding, M&A, exec moves & hiring — the signals that move deals
More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.
Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.
ARS Pharmaceuticals, Inc.
AI Executive Summary
AI-powered analysis of 8-K filing content
ARS Pharmaceuticals appointed Donn Casale as President effective June 1, 2026, bringing 25+ years of biopharmaceutical experience from his role as Chief Commercial Officer at Dynavax Technologies. This leadership transition signals the company's focus on strengthening commercial strategy and operational execution.
Key Takeaways
Donn Casale assumes the President role on June 1, 2026, following a CEO recommendation from Richard Lowenthal
Casale brings over 25 years of biopharmaceutical industry experience, most recently as Chief Commercial Officer at Dynavax Technologies since October 2017
2 more takeaways